var data={"title":"Nifedipine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nifedipine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6652?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nifedipine-drug-information\" class=\"drug drug_general\">see &quot;Nifedipine: Drug information&quot;</a> and <a href=\"topic.htm?path=nifedipine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nifedipine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201399\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adalat CC;</li>\n      <li>Afeditab CR;</li>\n      <li>Nifediac CC [DSC];</li>\n      <li>Nifedical XL [DSC];</li>\n      <li>Procardia;</li>\n      <li>Procardia XL</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201400\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adalat XL;</li>\n      <li>Nifedipine ER</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054394\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antianginal Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Calcium Channel Blocker</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Calcium Channel Blocker, Dihydropyridine</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054387\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=nifedipine-drug-information\" class=\"drug drug_general\">see &quot;Nifedipine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension, severe (urgency):</b> Limited data available: Children and Adolescents: Immediate release: Oral or &quot;bite and swallow&quot; (eg, bite capsule to release liquid contents then swallow): 0.04 to 0.25 mg/kg/dose; maximum single dose: 10 mg/dose; may repeat if needed every 4 to 6 hours; monitor carefully; typically reserved for inpatient use; maximum daily dose: 1 to 2 mg/kg/<b>day</b> (Blaszak 2001; Egger 2002; Singh 2012; Yui 2004). <b>Note:</b> Current pediatric blood pressure guidelines do not recommend use (NHBPEP 2004) since other safe and effective alternatives are available in the pediatric population (Flynn 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension; chronic therapy:</b> Limited data available: Children and Adolescents (able to swallow whole tablet): Extended release: Oral: Initial: 0.25 to 0.5 mg/kg/<b>day</b> once daily or divided in 2 doses every 12 hours; do not exceed initial adult daily dose of 30 to 60 mg/<b>day</b>; titrate dose to effect; maximum daily dose: 3 mg/kg/<b>day</b> up to 120 mg/<b>day</b> (AAP [Flynn 2017]; NHBPEP 2004; NHLBI 2011); some centers use a higher maximum dose: 3 mg/kg/<b>day</b> up to 180 mg<b>/day</b> (Flynn 2000).<b> Note:</b> Doses are usually titrated upward over 7 to 14 days; may increase over 3 days if clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>High altitude pulmonary edema</b> (Pollard 2001): Limited data available: Children and Adolescents: <b>Note:</b> Reserve treatment with NIFEdipine for unsatisfactory response to oxygen and/or altitude descent: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: 0.5 mg/kg/dose every 8 hours; maximum dose: 20 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release (preferred): 1.5 mg/kg/day given once daily or divided in 2 doses per <b>day</b>; maximum dose: 40 mg/dose; usual adult dose is 30 mg every 12 hours (Luks 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dosage adjustments should occur at 7- to 14-day intervals, to allow for adequate assessment of new dose; when switching from immediate release to sustained release formulations, use same total daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic stable or vasospastic angina:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate release: Initial: 10 mg 3 times daily; usual dose: 10 to 20 mg 3 times daily; coronary artery spasm may require up to 20 to 30 mg 3 to 4 times daily; single doses &gt;30 mg and total daily doses &gt;120 mg are rarely needed; maximum daily dose: 180 mg/<b>day</b>; <b>Note:</b> Do not use for acute anginal episodes; may precipitate myocardial infarction.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended release: Initial: 30 or 60 mg once daily titrate as clinically indicated; Doses &gt;90 mg daily should be used with caution and only if necessary; maximum: 120 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypertension:</b> Oral: Extended release: Initial: 30 or 60 mg once daily usual dosage range (ASH/ISH [Weber 2014]): 30 to 90 mg daily; maximum: 90 to 120 mg daily</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); the pharmacokinetics of nifedipine are not significantly influenced by the degree of renal impairment (only trace amounts of unchanged drug are found in urine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis effects: Supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); use with caution. Clearance of nifedipine is reduced in cirrhotic patients, which may lead to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201374\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procardia: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 30 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 30 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 60 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 90 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adalat CC: 90 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Afeditab CR: 30 mg, 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nifediac CC: 30 mg [DSC], 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nifedical XL: 30 mg [DSC], 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procardia XL: 30 mg, 60 mg, 90 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg, 60 mg, 90 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201360\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054398\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Liquid-filled capsule may be punctured and drug solution administered orally. When nifedipine is administered sublingually, only a small amount is absorbed sublingually; the observed effects are actually due to swallowing of the drug with subsequent rapid oral absorption. When measuring smaller doses from the liquid-filled capsules, completely empty the capsule to determine the concentration (may vary based on strength and by manufacturer) and administer the appropriate volume for the desired dose; the following concentrations are for Procardia: 10 mg capsule = 10 mg/0.34 mL; 20 mg capsule = 20 mg/0.45 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Tablets should be swallowed whole; do not crush, break, chew, or divide. Adalat CC, Afeditab CR: Administer on an empty stomach (per manufacturer); other extended release products may not have this recommendation; consult product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25226339\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adalat CC, Afeditab CR, Procardia XL: Store below 30&deg;C (86&deg;F); protect from light and moisture. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Nifediac CC, Nifedical XL: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light and moisture. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immediate release capsules (Procardia): Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); prevent capsules from freezing; protect from light and moisture. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054397\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate release: Treatment of chronic stable or vasospastic angina (FDA approved in adults); has also been used for treatment of hypertensive emergency and high altitude pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended release: Treatment of hypertension alone or in combination with other hypertensive agents; treatment of chronic stable or vasospastic angina (All indications: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201456\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">NIFEdipine may be confused with niCARdipine, niMODipine, nisoldipine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Procardia XL may be confused with Cartia XT</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Nifedipine (immediate release) is identified as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potential to cause hypotension and risk for precipitating myocardial ischemia (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Nifedipine (immediate release) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Depin [India] may be confused with Depen brand name for penicillamine [US]; Depon brand name for acetaminophen [Greece]; Dipen brand name for diltiazem [Greece]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nipin [Italy and Singapore] may be confused with Nipent brand name for pentostatin [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201454\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac failure, flushing (less common with extended release), palpitations, peripheral edema, transient hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, disturbed sleep, dizziness, equilibrium disturbance, fatigue, headache, jitteriness, mood changes, nervousness, shakiness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatitis, diaphoresis, pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, constipation, diarrhea, flatulence, gingival hyperplasia, heartburn, nausea, sore throat</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Sexual difficulty</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Joint stiffness, muscle cramps, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Chest congestion, cough, dyspnea, nasal congestion, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, inflammation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute generalized exanthematous pustulosis, agranulocytosis, alopecia, altered sense of smell, anemia, aplastic anemia, angina pectoris, angioedema, arthritis (with positive ANA), bezoar formation, cardiac arrhythmia, cerebral ischemia, depression, dysgeusia, epistaxis, extrapyramidal reaction, erectile dysfunction, erythema multiforme, erythromelalgia, exfoliative dermatitis, facial edema, gastroesophageal reflux disease, gastrointestinal obstruction, gastrointestinal ulcer, gynecomastia, hematuria, hepatitis (allergic), ischemia, leukopenia, malignant neoplasm of lip (Friedman 2012), memory impairment, migraine, myalgia, myoclonus, nocturia, paranoia, parotitis, periorbital edema, polyuria, purpura, skin photosensitivity, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, tinnitus, toxic epidermal necrolysis, transient blindness, ventricular arrhythmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201381\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to nifedipine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Considered contraindicated in patients with ST-elevation myocardial infarction (STEMI) (ACCF/AHA [O'Gara 2013]); avoid use (Elkayam 1990; Yancy 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe hypotension; cardiovascular shock; breast-feeding; pregnancy or women of childbearing potential. <b>Note:</b> SOGC and ACOG guidelines recommend nifedipine as a preferred agent for maternal hypertension (ACOG 2013; SOGC [Magee 2014]). Extended release only: Hypersensitivity to other dihydropyridine calcium antagonists; Kock pouch (ileostomy after proctocolectomy); moderate or severe hepatic impairment; severe gastrointestinal obstructive disorders, concomitant use with rifampicin</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201364\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angina/MI: Increased angina and/or MI have occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade. In patients with unstable angina/non-STEMI, the use of immediate-release nifedipine is not recommended except with concomitant beta-blockade (ACCF/AHA [Anderson 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. <b>The use of immediate release nifedipine (sublingually or orally) in hypertensive emergencies and urgencies is neither safe nor effective.</b> Serious adverse events (eg, death, cerebrovascular ischemia, syncope, stroke, acute myocardial infarction, and fetal distress) have been reported.<b> Immediate release nifedipine should not be used for acute blood pressure reduction.</b> Guidelines are available when immediate release nifedipine is required for acute treatment in pregnant or postpartum women (ACOG 692 2017; Magee 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral edema: The most common side effect is peripheral edema; occurs within 2 to 3 weeks of starting therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in myocardial ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI strictures: Alterations in GI anatomy (eg, severe GI narrowing, history of GI cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty) and underlying hypomotility disorders have led to bezoar formation with extended release forms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: The ACCF/AHA heart failure guidelines recommend to avoid use in patients with HF due to lack of benefit and/or worse outcomes with calcium channel blockers in general (Yancy 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Clearance of nifedipine is reduced in cirrhotic patients leading to increased systemic exposure; monitor closely for adverse effects/toxicity and consider dose adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release formulation: Consists of drug within a nondeformable matrix; following drug release/absorption, the matrix/shell is expelled in the stool. The use of nondeformable products in patients with known stricture/narrowing of the GI tract (eg, severe gastrointestinal narrowing, colon cancer, obstruction, bowel resection, gastric bypass, vertical banded gastroplasty) has been associated with symptoms of obstruction (pharmacobezoar).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immediate release formulation: Immediate release formulations should not be used to manage primary hypertension, adequate studies to evaluate outcomes have not been conducted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Adalat CC tablets contain lactose; do not use with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption syndromes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Use with caution before major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia may result in severe hypotension and/or increased fluid requirements. Consider withdrawing nifedipine (&gt;36 hours) before surgery if possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Abrupt withdrawal may cause rebound angina in patients with CAD.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201443\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201369\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12643&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May increase the serum concentration of NIFEdipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.<b> Exceptions: </b>Fluconazole; Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: NIFEdipine may enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: May increase the serum concentration of NIFEdipine. Reported with sustained release nifedipine product.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of NIFEdipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: NIFEdipine may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: May enhance the adverse/toxic effect of NIFEdipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of NIFEdipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide.  Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nafcillin: May decrease the serum concentration of NIFEdipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: NIFEdipine may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of NIFEdipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some US and Canadian calcium channel blockers contraindicate use with rifampin, however recommendations vary. Consult appropriate labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of NIFEdipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine: NIFEdipine may increase the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): NIFEdipine may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201395\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Nifedipine serum levels may be decreased if taken with food. Food may decrease the rate but not the extent of absorption of Procardia XL. Increased nifedipine concentrations resulting in therapeutic and vasodilator side effects, including severe hypotension and myocardial ischemia, may occur if nifedipine is taken by patients ingesting grapefruit. Management: Avoid grapefruit/grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201370\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201385\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Nifedipine crosses the placenta (Manninen 1991; Silberschmidt 2008). An increase in perinatal asphyxia, cesarean delivery, prematurity, and intrauterine growth retardation have been reported following maternal use.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension is also associated with adverse events in the fetus, infant, and mother. If treatment for chronic hypertension during pregnancy is needed, nifedipine is one of the preferred agents (ACOG 2013; SOGC [Magee 2014]). Nifedipine is also recommended for the management of acute onset, severe hypertension (systolic BP &ge;160 mm Hg or diastolic BP &ge;110 mm Hg) with preeclampsia or eclampsia in pregnant and postpartum women (ACOG 692 2017; Magee 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Nifedipine has also been evaluated for the treatment of preterm labor. Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG 171 2016). Nifedipine is ineffective for maintenance tocolytic therapy (ACOG 171 2016; Roos 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1054393\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, platelets, periodic liver enzymes; blood pressure, heart rate, signs and symptoms of CHF, peripheral edema </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201363\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina; also reduces peripheral vascular resistance, producing a reduction in arterial blood pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201380\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immediate release: ~20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding (concentration dependent): 92% to 98%; <b>Note:</b> Protein-binding may be significantly decreased in patients with renal or hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Capsule: 40% to 77%; ER: 65% to 89% relative to immediate release capsules; bioavailability increased with significant hepatic disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Adults: Healthy: 2 to 5 hours; Cirrhosis: 7 hours; Elderly: 7 hours (extended release tablet)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (60% to 80% as inactive metabolites); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10951001\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>4 mg/mL Oral Suspension (ASHP Standard Concentration) (ASHP 2017)</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 4 mg/mL oral suspension may be made with liquid capsules (<b>Note:</b> Concentration inside capsule may vary depending on manufacturer. Procardia: 10 mg capsule contains a concentration of 10 mg/0.34 mL [29.4 mg/mL]). Puncture the top of twelve 10 mg liquid capsules with one needle to create a vent. Insert a second needle attached to a syringe and extract the liquid; transfer to a calibrated bottle and add sufficient quantity of a 1:1 mixture of Ora-Sweet and Ora-Plus to make 30 mL. Label &quot;shake well&quot;. Stable 90 days under refrigeration or at room temperature.</p>\n    <div class=\"reference\">Nahata MC, Morosco RS, and Willhite EA, &quot;Stability of Nifedipine in Two Oral Suspensions Stored at Two Temperatures,&quot; <i>J Am Pharm Assoc</i>, 2002, 42(6):865-7.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201384\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (NIFEdipine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $106.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $230.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Procardia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $329.54</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Adalat CC Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $213.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $358.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $419.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Afeditab CR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $125.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $224.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (NIFEdipine ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $139.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $248.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $302.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (NIFEdipine ER Osmotic Release Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $132.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $229.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $256.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Procardia XL Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $743.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,286.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $1,484.72</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201388\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adalat (AE, AR, AT, BE, BF, BH, BJ, BR, CH, CI, CL, CR, CZ, DE, DK, DO, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IT, JO, JP, KE, KR, KW, LR, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NO, PA, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SL, SN, SV, TN, TR, TZ, UA, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Adalat 10 (AU);</li>\n      <li>Adalat 20 (AU);</li>\n      <li>Adalat CC (BB);</li>\n      <li>Adalat CR (BG, CH, CY, GR, JP, RO, TH);</li>\n      <li>Adalat Crono (IT);</li>\n      <li>Adalat GITS (CN, HK);</li>\n      <li>Adalat GITS 30 (PH);</li>\n      <li>Adalat L (JP);</li>\n      <li>Adalat LA (BH, ET, GB, KW, LB, MT, MY, SG);</li>\n      <li>Adalat LP (FR);</li>\n      <li>Adalat Oros (AU, BM, BR, BS, BZ, CL, CO, DK, EC, EE, ES, FI, GY, ID, IS, JM, KR, LU, NL, NO, NZ, PE, PR, PY, SE, SI, SR, TT, TW, UY, VE);</li>\n      <li>Adalat Retard (AE, AT, BF, BH, BJ, CI, CL, CR, CZ, DE, EG, ES, ET, GB, GH, GM, GN, GR, GT, HK, HN, ID, IQ, IR, JO, KE, KW, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, OM, PA, PE, PH, PL, PY, QA, SA, SC, SD, SL, SN, SV, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Adalate (FR);</li>\n      <li>Addos XR (AU);</li>\n      <li>Adefin (AU);</li>\n      <li>Adefin XL (AU);</li>\n      <li>Adifen SR (MY);</li>\n      <li>Adipine XL (GB);</li>\n      <li>Alonix-S (TW);</li>\n      <li>Altapres (PH);</li>\n      <li>Ampine (BD);</li>\n      <li>Aprical (DE, LU);</li>\n      <li>Atanaal Softcap (TW);</li>\n      <li>Calcibloc (PH);</li>\n      <li>Calcibloc OD (PH);</li>\n      <li>Calcicor (ET);</li>\n      <li>Calcigard (IN, SG, TH);</li>\n      <li>Calcigard Retard (ZW);</li>\n      <li>Cardifen (ZA);</li>\n      <li>Cardiiopine (AE);</li>\n      <li>Chronadalate LP (FR);</li>\n      <li>Citilat (IT);</li>\n      <li>Coracten (AE, BH, CY, DE, EG, GB, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Coral (IT);</li>\n      <li>Cordaflex (BG, HU, VN);</li>\n      <li>Cordilat (MX);</li>\n      <li>Cordipen (SG);</li>\n      <li>Cordipen Retard (SG);</li>\n      <li>Cordipin (HK, HR);</li>\n      <li>Cordipin Retard (HR);</li>\n      <li>Cordipin XL (HR, LV);</li>\n      <li>Corinfar (HU, LV);</li>\n      <li>Corinfar Retard (LV);</li>\n      <li>Corotrend (DE);</li>\n      <li>Depin (IN);</li>\n      <li>Depin-E Retard (TH);</li>\n      <li>Dignokonstant (DE);</li>\n      <li>Dipinkor (ID);</li>\n      <li>Duranifin (DE);</li>\n      <li>Ecodipin (CH);</li>\n      <li>Epilat (QA);</li>\n      <li>Fenamon (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Glopir (GR);</li>\n      <li>Hexadilat (DK);</li>\n      <li>Huma-Nifedin (HU);</li>\n      <li>Jutadilat (DE);</li>\n      <li>Kin Ran (CN);</li>\n      <li>Kordypin (UA);</li>\n      <li>Kordypin XL (UA);</li>\n      <li>Myogard (AE, BH, CY, EG, IN, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Nedipin (TW);</li>\n      <li>Nelapine (PH);</li>\n      <li>Nepin SR (LK);</li>\n      <li>Nicardia (TH);</li>\n      <li>Nicardia CD (TH);</li>\n      <li>Nicardia Retard (TH);</li>\n      <li>Nicardia XL (LK);</li>\n      <li>Nidipin (HU);</li>\n      <li>Nifa (BD);</li>\n      <li>Nifadil (HR);</li>\n      <li>Nifangin (FI);</li>\n      <li>Nifar (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Nifar-GB (MX);</li>\n      <li>Nifdemin (FI);</li>\n      <li>Nifebene (AT);</li>\n      <li>Nifecap (BD);</li>\n      <li>Nifecard (AE, AT, BH, HR, JO, SA);</li>\n      <li>Nifecard XL (SG);</li>\n      <li>Nifecor (DE);</li>\n      <li>Nifedepat (DE);</li>\n      <li>Nifedicor (IT);</li>\n      <li>Nifedigel (MX);</li>\n      <li>NIfedilat (ZA);</li>\n      <li>Nifedilong (IL);</li>\n      <li>Nifedin (IT);</li>\n      <li>Nifedine (IN);</li>\n      <li>Nifedipin (HR);</li>\n      <li>Nifedipin AL (HU);</li>\n      <li>Nifedipin Pharmavit (HU);</li>\n      <li>Nifedipin Stada (LU);</li>\n      <li>Nifedipin-ratiopharm (LU);</li>\n      <li>Nifedipresc MR (GB);</li>\n      <li>Nifedix SR (KR);</li>\n      <li>Nifehexal (LU, VN);</li>\n      <li>Nifelan (EC);</li>\n      <li>Nifelat (AR, ET, HK, MT, SG, TH, ZW);</li>\n      <li>Nifelat Q (TR);</li>\n      <li>Nifelat R (ZW);</li>\n      <li>Nifelat-Q (TH);</li>\n      <li>Nifensar (PE);</li>\n      <li>Nifensar Retard (PE);</li>\n      <li>Niferon CR (KR);</li>\n      <li>Nifeslow (LU);</li>\n      <li>Nifestad (PH);</li>\n      <li>Nifezzard (MX);</li>\n      <li>Nificard (CY, EG, IQ, IR, KW, LB, LY, OM, QA, SY, YE);</li>\n      <li>Nifin (BD);</li>\n      <li>Nifipen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nipen (BD);</li>\n      <li>Noviken LP (MX);</li>\n      <li>Nyefax (AU);</li>\n      <li>Nyefax Retard (NZ);</li>\n      <li>Odipin (PH);</li>\n      <li>Orix (GR);</li>\n      <li>Osmo-Adalat (IL);</li>\n      <li>Pidilat (DE);</li>\n      <li>Pressolat (IL);</li>\n      <li>Sepamit (JP);</li>\n      <li>Servidipine (MY);</li>\n      <li>Slow-Nifine (LU);</li>\n      <li>Unidipin (HU, LU);</li>\n      <li>Zenusin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adalat CC extended release tablet (nifedipine) [prescribing information]. Pine Brook, NJ: Almatica Pharma Inc.; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), &quot;ACOG Practice Bulletin No. 125: Chronic Hypertension in Pregnancy,&quot; <i>Obstet Gynecol</i>, 2012, 119(2 Pt 1):396-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/22270315/pubmed\" target=\"_blank\" id=\"22270315\">22270315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), &quot;ACOG Practice Bulletin No. 127: &ldquo;Management of Preterm Labor,&rdquo;<i>Obstet Gynecol</i>, 2012, 119(6):1308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/22617615/pubmed\" target=\"_blank\" id=\"22617615\">22617615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25611642\"></a>American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2015;125(2):521-525. doi: 10.1097/01.AOG.0000460762.59152.d7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/25611642/pubmed\" target=\"_blank\" id=\"25611642\">25611642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adcock KG and Wilson JT, &ldquo;Nifedipine Labeling Illustrates the Pediatric Dilemma for Off-Patent Drugs,&rdquo; <i>Pediatrics</i>, 2002, 109(2):319-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/11826214/pubmed\" target=\"_blank\" id=\"11826214\">11826214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JE, Held N, Wright K. Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding. <i>Pediatrics</i>. 2004;113(4):e360-364.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/15060268/pubmed\" target=\"_blank\" id=\"15060268\">15060268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(23):e663-e828. doi: 10.1161/CIR.0b013e31828478ac.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/23630129/pubmed\" target=\"_blank\" id=\"23630129\">23630129</a>]</span><span class=\"doi\">10.1161/CIR.0b013e31828478ac</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antman EM, Anbe DT, Armstrong PW, et al, &quot;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&quot; <i>Circulation</i>, 2004, 110(9):e82-292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/15339869/pubmed\" target=\"_blank\" id=\"15339869\">15339869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barrett ME, Heller MM, Stone HF, et al, &quot;Raynaud Phenomenon of the Nipple in Breastfeeding mothers: An Underdiagnosed Cause of Nipple Pain,&quot; <i>JAMA Dermatol</i>, 2013, 149(3):300-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/23682366/pubmed\" target=\"_blank\" id=\"23682366\">23682366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26881962\"></a>Berens P, Eglash A, Malloy M, Steube AM. ABM clinical protocol #26: persistent pain with breastfeeding. <i>Breastfeed Med</i>. 2016;11(2):46-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/26881962/pubmed\" target=\"_blank\" id=\"26881962\">26881962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blaszak RT, Savage JA, and Ellis EN, &quot;The Use of Short-Acting Nifedipine in Pediatric Patients With Hypertension,&quot; <i>J Pediatr</i>, 2001, 139(1):34-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/11445791/pubmed\" target=\"_blank\" id=\"11445791\">11445791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo; <i>JAMA</i>, 2003, 289(19):2560-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/12748199 /pubmed\" target=\"_blank\" id=\"12748199 \">12748199 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dilmen U, Cagf&uuml;lar MK, Senses A, et al, &ldquo;Nifedipine in Hypertensive Emergencies of Children,&rdquo; <i>Am J Dis Child</i>, 1983, 137(12):1162-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/6637932 /pubmed\" target=\"_blank\" id=\"6637932 \">6637932 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Egger DW, Deming DD, Hamada N, et al, &quot;Evaluation of the Safety of Short-Acting Nifedipine in Children With Hypertension,&quot; <i>Pediatr Nephrol</i>, 2002, 17(1):35-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/11793132/pubmed\" target=\"_blank\" id=\"11793132\">11793132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ehrenkranz RA, Ackerman BA, and Hulse JD, &quot;Nifedipine Transfer Into Human Milk,&quot; <i>J Pediatr</i>, 1989, 114(3):478-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/2921695/pubmed\" target=\"_blank\" id=\"2921695\">2921695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT and Pasko DA, &ldquo;Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,&rdquo; <i>Pediatr Nephrol</i>, 2000, 15(3-4):302-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/ 11149130 /pubmed\" target=\"_blank\" id=\" 11149130 \"> 11149130 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/28827377/pubmed\" target=\"_blank\" id=\"28827377\">28827377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT. Safety of short-acting nifedipine in children with severe hypertension. <i>Expert Opin Drug Saf</i>. 2003;2(2):133-139.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman GD, Asgari MM, Warton EM, et al, &quot;Antihypertensive Drugs and Lip Cancer in Non-Hispanic Whites,&quot; <i>Arch Intern Med</i>, 2012, 6:1-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/22869299/pubmed\" target=\"_blank\" id=\"22869299\">22869299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garrison CP. Nipple vasospasms, Raynaud's syndrome, and nifedipine. <i>J Hum Lact</i>. 2002;18(4):382-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/12449056/pubmed\" target=\"_blank\" id=\"12449056\">12449056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez-Herce J, Albajara L, Cagigas P, et al, &ldquo;Treatment of Hypertensive Crisis in Children With Nifedipine,&rdquo; <i>Intensive Care Med</i>, 1988, 14(5):519-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/3221006/pubmed\" target=\"_blank\" id=\"3221006\">3221006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. <i>Wilderness Environ Med</i>. 2014;25(4 Suppl):S4-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/25498261/pubmed\" target=\"_blank\" id=\"25498261\">25498261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Helewa M, Moutquin JM, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. <i>J Obstet Gynaecol Can</i>. 2008;30(suppl 3):S1-S48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/18817592/pubmed\" target=\"_blank\" id=\"18817592\">18817592</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manninen AK and Juhakoski A, &quot;Nifedipine Concentrations in Maternal and Umbilical Serum, Amniotic Fluid, Breast Milk and Urine of Mothers and Offspring,&quot; <i>Int J Clin Pharmacol Res</i>, 1991, 11(5):231-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/1814844/pubmed\" target=\"_blank\" id=\"1814844\">1814844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute, &ldquo;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&rdquo; <i>Clinical Practice Guidelines</i>, 2011, National Institutes of Health. Available at <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Accessed: June 11, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &quot;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&quot; <i>Pediatrics</i>, 2004, 114(2 Suppl):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nifedipine capsule [prescribing information]. Eatontown, NJ: Heritage Pharmaceuticals Inc.; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17018510\"></a>Page SM, McKenna DS. Vasospasm of the nipple presenting as painful lactation. <i>Obstet Gynecol</i>. 2006;108(3 Pt 2):806-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/17018510/pubmed\" target=\"_blank\" id=\"17018510\">17018510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penny WJ and Lewis MJ, &quot;Nifedipine Is Excreted in Human Milk,&quot; <i>Eur J Clin Pharmacol</i>, 1989, 36(4):427-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/2737237/pubmed\" target=\"_blank\" id=\"2737237\">2737237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollard AJ, Niermeyer S, Barry P, et al, &quot;Children at High Altitude: An International Consensus Statement by an Ad Hoc Committee of the International Society for Mountain Medicine, March 12, 2001,&quot; <i>High Alt Med Biol</i>, 2001, 2(3):389-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/11682018/pubmed\" target=\"_blank\" id=\"11682018\">11682018</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procardia (nifedipine) [prescribing information]. New York, NY: Pfizer; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procardia XL (nifedipine) [prescribing information]. New York, NY: Pfizer; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roos C, Spaanderman ME, Schuit E, et al, &quot;Effect of Maintenance Tocolysis With Nifedipine in Threatened Preterm Labor on Perinatal Outcomes: a Randomized Controlled Trial,&quot; <i>JAMA</i>, 2013, 309(1):41-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/23280223/pubmed\" target=\"_blank\" id=\"23280223\">23280223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosen WJ and Johnson CE, &ldquo;Evaluation of Five Procedures for Measuring Nonstandard Doses of Nifedipine Liquid,&rdquo; <i>Am J Hosp Pharm</i>, 1989, 46(11):2313-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/2589350/pubmed\" target=\"_blank\" id=\"2589350\">2589350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silberschmidt AL, Kuhn-Velten WN, Juon AM, et al, &ldquo;Nifedipine Concentration in Maternal and Umbilical Cord Blood After Nifedipine Gastrointestinal Therapeutic System for Tocolysis,&rdquo; <i>BJOG</i>, 2008, 115(4):480-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/18271884 /pubmed\" target=\"_blank\" id=\"18271884 \">18271884 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh D, Akingbola O, Yosypiv I, et al, &quot;Emergency Management of Hypertension in Children,&quot; <i>Int J Nephrol</i>, 2012, 2012:420247.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/22577545/pubmed\" target=\"_blank\" id=\"22577545\">22577545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wu M, Chason R, and Wong M, &quot;Raynaud's Phenomenon of the Nipple,&quot; <i>Obstet Gynecol</i>, 2012, 119(2 Pt 2):447-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/22270434/pubmed\" target=\"_blank\" id=\"22270434\">22270434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yiu V, Orrbine E, Rosychuk RJ, et al, &quot;The Safety and Use of Short-Acting Nifedipine in Hospitalized Hypertensive Children,&quot; <i>Pediatr Nephrol</i>, 2004, 19(6):644-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nifedipine-pediatric-drug-information/abstract-text/15054645/pubmed\" target=\"_blank\" id=\"15054645\">15054645</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12643 Version 239.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201399\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F201400\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1054394\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1054387\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201374\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F201360\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1054398\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25226339\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1054397\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F201456\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201454\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201381\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201364\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F201443\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201369\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F201395\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F201370\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F201385\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1054393\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201363\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F201380\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10951001\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F201384\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F201388\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12643|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nifedipine-drug-information\" class=\"drug drug_general\">Nifedipine: Drug information</a></li><li><a href=\"topic.htm?path=nifedipine-patient-drug-information\" class=\"drug drug_patient\">Nifedipine: Patient drug information</a></li></ul></div></div>","javascript":null}